Scynexis SCYX
NASDAQ SCYX
$4.91 -0.24 (-4.66%)
At close: Sep 9, 2026 · 4:00 PM EDT

Scynexis (SCYX) Non-Current Assets (2013 - 2026)

Scynexis' (SCYX) quarterly Non-Current Assets came in at $18.7 million in Q2 2026, up 346.47% on a YoY basis from $4.2 million in Q2 2025, and up 25.44% quarter-over-quarter from $14.9 million in Q1 2026.

Analysis

Scynexis (SCYX) Non-Current Assets (2013 - 2026) Analysis & Trends

Scynexis (SCYX) has reported Non-Current Assets for 14 consecutive years, with $18.7 million the latest figure, recorded in Q2 2026.

  • For the quarter ending Q2 2026, Non-Current Assets rose 346.47% year-over-year to $18.7 million; the trailing twelve-month figure through Jun 2026 stood at $54.7 million (down 3.91% YoY), and the FY2025 full-year result was $18.7 million, up 1.03% from the prior year.
  • Non-Current Assets advanced to $18.7 million in Q2 2026 per SCYX's latest filing, from $14.9 million in the prior quarter.
  • Across five years, Non-Current Assets topped out at $26.3 million in Q4 2023 and bottomed at $2.4 million in Q3 2025.
  • Historically, Non-Current Assets has averaged $13.6 million across 5 years, with a median of $14.1 million in 2024.
  • The sharpest annual moves came in 2025 and 2026: Non-Current Assets plunged 87.2% in 2025, then surged 346.47% in 2026.
  • Over 5 years, Non-Current Assets stood at $8.7 million in 2022, then soared by 200.56% to $26.3 million in 2023, then retreated by 29.79% to $18.5 million in 2024, then increased by 1.03% to $18.7 million in 2025, then gained by 0.43% to $18.7 million in 2026.
  • According to Business Quant data, Non-Current Assets over the past three periods registered $18.7 million, $14.9 million, and $18.7 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Non-Current Assets (Qtr)
1 Amgen 211.73 Bn 197.74 Bn 7.24 Bn 60.68 Bn
2 Gilead Sciences 180.92 Bn 177.74 Bn 6.22 Bn 35.42 Bn
3 Vertex Pharmaceuticals 132.16 Bn 124.30 Bn 2.84 Bn 14.88 Bn
4 Regeneron Pharmaceuticals 82.89 Bn 74.90 Bn 3.93 Bn 23.28 Bn
5 Argenx Se 61.41 Bn 56.23 Bn 1.37 Bn 1.96 Bn
6 Moderna 53.99 Bn 48.85 Bn 52.00 Mn 5.15 Bn
7 Alnylam Pharmaceuticals 34.48 Bn 31.18 Bn 992.69 Mn 938.60 Mn
8 Biogen 31.15 Bn 29.86 Bn 1.96 Bn 24.78 Bn
9 Roivant Sciences 30.05 Bn 30.05 Bn 1.16 Mn 564.41 Mn
10 Scynexis 58.41 Mn -56.29 Mn - 18.73 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 18.73 Mn
Mar 31, 2026 14.94 Mn
Dec 31, 2025 18.65 Mn
Sep 30, 2025 2.38 Mn
Jun 30, 2025 4.20 Mn
Mar 31, 2025 15.69 Mn
Dec 31, 2024 18.46 Mn
Sep 30, 2024 18.58 Mn
Jun 30, 2024 13.23 Mn
Mar 31, 2024 16.58 Mn
Dec 31, 2023 26.30 Mn
Sep 30, 2023 19.91 Mn
Jun 30, 2023 9.33 Mn
Mar 31, 2023 10.53 Mn
Dec 31, 2022 8.75 Mn
Sep 30, 2022 8.73 Mn
Jun 30, 2022 9.94 Mn
Mar 31, 2022 9.66 Mn
Dec 31, 2021 10.46 Mn
Sep 30, 2021 5.95 Mn